Scarica l'app Stockscreener
485.36
1.34%
6.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$478.93
Aprire:
$483.81
Volume 24 ore:
297.13K
Relative Volume:
0.73
Capitalizzazione di mercato:
$20.90B
Reddito:
$3.13B
Utile/perdita netta:
$1.27B
Rapporto P/E:
18.40
EPS:
26.3851
Flusso di cassa netto:
$1.12B
1 W Prestazione:
+3.38%
1M Prestazione:
-3.45%
6M Prestazione:
+60.50%
1 anno Prestazione:
+37.20%
Intervallo 1D:
$481.95
$489.50
Intervallo di 1 settimana:
$466.01
$489.50
Portata 52W:
$266.98
$519.99
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
485.36 | 20.62B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.89 | 56.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
127.42 | 55.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.98 | 48.36B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.69 | 40.01B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data - simplywall.st
Aug Fed Impact: Will United Therapeutics Corporation benefit from government policyJuly 2025 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
United Therapeutics Corporation $UTHR Shares Purchased by AE Wealth Management LLC - MarketBeat
United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring A 13% Upside Potential - DirectorsTalk Interviews
Bank of New York Mellon Corp Sells 11,016 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Summit Global Investments Sells 3,327 Shares of United Therapeutics Corporation $UTHR - MarketBeat
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Yahoo Finance
A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Finviz
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) - Finviz
Mutual of America Capital Management LLC Acquires 4,036 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 13,401 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Strs Ohio Has $4.22 Million Stake in United Therapeutics Corporation $UTHR - MarketBeat
What's Going On With United Therapeutics Stock Monday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics reports positive phase 1 results for bioengineered liver By Investing.com - Investing.com Canada
How Investors May Respond To United Therapeutics (UTHR) Positive Early Data For Bioengineered Liver Support Device - Yahoo Finance
United Therapeutics reports positive phase 1 results for bioengineered liver - Investing.com
Retirement Systems of Alabama Sells 18,709 Shares of United Therapeutics Corporation $UTHR - MarketBeat
World’s first FDA-cleared bioengineered liver trial meets survival goal - Stock Titan
United Therapeutics appoints biomedical research leader to board By Investing.com - Investing.com Nigeria
United Therapeutics Appoints Kevin J. Tracey To Board - citybiz
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to Board of Directors, Effective January 21, 2026 - marketscreener.com
United Therapeutics appoints biomedical research leader to board - Investing.com
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors - United Therapeutics Investor Relations
Element Squared LLC Buys 5,027 Shares of United Therapeutics Corp (UTHR) - GuruFocus
Marquette Asset Management, LLC Buys 1 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corporation (UTHR): A Bull Case Theory - Finviz
Polaris Capital Management LLC Sells 5,600 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Reassessing United Therapeutics (UTHR) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension - TipRanks
United Therapeutics Corporation $UTHR Shares Sold by State of Alaska Department of Revenue - MarketBeat
SG Americas Securities LLC Purchases 7,483 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Position Decreased by Nepsis Inc. - MarketBeat
How United Therapeutics Corporation (UTH) stock expands through international marketsTreasury Yields & Verified Swing Trading Watchlists - Улправда
Is United Therapeutics Corporation stock a good choice for value investorsJuly 2025 Recap & AI Enhanced Execution Alerts - Улправда
MannKind Provides Business Updates and 2026 Growth Drivers - Benzinga
Robeco Institutional Asset Management B.V. Has $38.19 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) COO Sells $7,127,932.50 in Stock - MarketBeat
Director Jan Malcolm Sells Shares of United Therapeutics Corp - GuruFocus
United Therapeutics (UTHR): UBS Raises Price Target, Maintains B - GuruFocus
Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Performance Tethered To Its Attractive Financial Prospects? - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares - MarketBeat
United Therapeutics Corporation (UTHR) Stock Analysis: A Healthcare Giant with Strong Growth Potential and Robust Analyst Support - DirectorsTalk Interviews
Biotech developing organ transplant tech steps onto J.P. Morgan stage - Stock Titan
United Therapeutics Corporation $UTHR Shares Bought by Merit Financial Group LLC - MarketBeat
Allspring Global Investments Holdings LLC Acquires 4,944 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics Corporation $UTHR Position Increased by Cwm LLC - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 137,900 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Feb 05 '26 |
Sale |
483.25 |
8,300 |
4,010,940 |
36,781 |
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):